BTIG Research Reiterates “Buy” Rating for Solventum (NYSE:SOLV)

Solventum (NYSE:SOLV)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a report released on Monday, Benzinga reports. They currently have a $95.00 target price on the stock. BTIG Research’s target price would indicate a potential upside of 8.66% from the stock’s current price.

A number of other research analysts have also recently issued reports on SOLV. Weiss Ratings upgraded shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Stifel Nicolaus lifted their target price on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wedbush upped their target price on shares of Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. KeyCorp increased their price objective on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Mizuho set a $113.00 target price on Solventum in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Solventum currently has an average rating of “Moderate Buy” and an average target price of $92.80.

Solventum Stock Down 0.0%

Shares of NYSE:SOLV opened at $87.43 on Monday. The business’s 50 day simple moving average is $85.15 and its two-hundred day simple moving average is $76.58. The firm has a market cap of $14.88 billion, a P/E ratio of 10.69, a PEG ratio of 1.36 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. Solventum has a 52-week low of $62.38 and a 52-week high of $94.16.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.64. The business had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. Solventum’s revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, research analysts forecast that Solventum will post 7.22 EPS for the current fiscal year.

Institutional Trading of Solventum

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BOKF NA boosted its holdings in shares of Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after buying an additional 141 shares during the period. Smartleaf Asset Management LLC boosted its stake in Solventum by 23.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock worth $60,000 after purchasing an additional 142 shares during the period. NewEdge Advisors LLC raised its stake in Solventum by 2.2% during the 1st quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock valued at $438,000 after purchasing an additional 144 shares during the period. Deseret Mutual Benefit Administrators raised its stake in Solventum by 39.5% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 516 shares of the company’s stock valued at $41,000 after purchasing an additional 146 shares during the period. Finally, HB Wealth Management LLC lifted its holdings in shares of Solventum by 3.5% in the first quarter. HB Wealth Management LLC now owns 4,292 shares of the company’s stock valued at $280,000 after purchasing an additional 147 shares in the last quarter.

About Solventum

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.